We are live on ! Find out more
SGMT icon

Sagimet Biosciences
SGMT

72 hedge funds and large institutions have $86.7M invested in Sagimet Biosciences in 2025 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

112% more call options, than puts

Call options by funds: $2.85M | Put options by funds: $1.34M

75% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 12

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

7% more funds holding

Funds holding: 67 → 72 (+5)

2.69% more ownership

Funds ownership: 38.06% → 40.76% (+2.7%)

3% less capital invested

Capital invested by funds: $89M → $86.7M (-$2.31M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
72
Holders Change
+5
Holders Change %
+7.46%
% of All Funds
0.94%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
20
Increased
21
Reduced
12
Closed
14
Calls
$2.85M
Puts
$1.34M
Net Calls
+$1.51M
Net Calls Change
-$205K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$5.68M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$4.52M
3
SSA
Schonfeld Strategic Advisors
New York
+$3.49M
4
AAA
Affinity Asset Advisors
New York
+$2.84M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.06M

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$8.52M
2
UBS Group
UBS Group
Switzerland
-$2.16M
3
JF
Jump Financial
Illinois
-$1.13M
4
BCM
Bridgeway Capital Management
Texas
-$918K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$883K
Name Holding Trade Value Shares
Change 		Change in
Stake
Rockefeller Capital Management
51
Rockefeller Capital Management
New York
$61.7K +$73K +9,000 New
Wells Fargo
52
Wells Fargo
California
$48K +$4.05K +500 +8%
Barclays
53
Barclays
United Kingdom
$44K +$52K +6,409 New
AP
54
Antipodes Partners
Australia
$21.8K -$18.1K -2,236 -41%
GRP
55
Global Retirement Partners
California
$20.6K – – –
NFSG
56
Newbridge Financial Services Group
Florida
$10.3K – – –
US Bancorp
57
US Bancorp
Minnesota
$6.86K +$8.11K +1,000 New
TFA
58
Toth Financial Advisory
Virginia
$4.46K – – –
Federated Hermes
59
Federated Hermes
Pennsylvania
$3.86K +$4.57K +563 New
TRCT
60
Tower Research Capital (TRC)
New York
$3.71K -$33K -4,066 -88%
MCM
61
MAI Capital Management
Ohio
$3.43K -$2.12K -261 -34%
Royal Bank of Canada
62
Royal Bank of Canada
Ontario, Canada
$3K -$2.85K -351 -40%
RWM
63
Rialto Wealth Management
New York
$2.46K – – –
BNP Paribas Financial Markets
64
BNP Paribas Financial Markets
France
$2.45K -$214K -26,428 -99%
PWA
65
Physician Wealth Advisors
Utah
$2.17K – – –
RA
66
Rise Advisors
New York
$2.1K – – –
Fidelity Investments
67
Fidelity Investments
Massachusetts
$1.23K +$973 +120 +203%
AAP
68
Arax Advisory Partners
Colorado
$789 +$933 +115 New
JP Morgan Chase
69
JP Morgan Chase
New York
$672 – – –
PE
70
Point72 Europe
United Kingdom
$357 +$422 +52 New
FFA
71
Farther Finance Advisors
California
$268 +$316 +39 New
SS
72
SBI Securities
Japan
$247 +$211 +26 +260%
JF
73
Jump Financial
Illinois
– -$1.13M -148,351 Closed
PHS
74
PFM Health Sciences
California
– -$686K -90,000 Closed
HF
75
HRT Financial
New York
– -$532K -69,909 Closed
1 2
3
4

SGMT Hedge Fund Activity: Q3 2025 in Review

72 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q3 2025, worth a combined $86.7M — down 2.6% from $89M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new SGMT positions and 14 closed out — a net gain of 6 holders — while 21 added to existing stakes and 12 trimmed.

The largest buyer was Millennium Management, adding an estimated $5.68M. The largest seller was Woodline Partners, cutting an estimated $8.52M.

  • 72 institutional investors held Sagimet Biosciences (SGMT) as of Q3 2025, up from 67 in Q2 2025.
  • Funds reported $86.7M of Sagimet Biosciences stock for Q3 2025, down 2.6% quarter-over-quarter.
  • 20 funds opened new Sagimet Biosciences positions in Q3 2025 and 14 closed out, a net change of +6 holders.
  • The largest Sagimet Biosciences buyer in Q3 2025 was Millennium Management, an estimated $5.68M added.
  • The largest Sagimet Biosciences seller in Q3 2025 was Woodline Partners, an estimated $8.52M sold.

Based on aggregated 13F filings for Q3 2025.